US45257U1088 - Common Stock
7.73 +0.03 (+0.39%)
After market: 7.73 0 (0%)
NASDAQ:IMNM (12/8/2023, 7:00:02 PM)After market: 7.73 0 (0%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Exton, Pennsylvania and currently employs 37 full-time employees. The company went IPO on 2020-10-02. The Company’s portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, targeted effectors, radioligand therapies and ADCs. Its proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of antibodies and targets. Its lead discovery programs include Oncology (IMM-ONC-01) and SARS-CoV-2 (IMM-BCP-01). Its IMM-ONC-01 is its lead oncology program targets interleukin 38 (IL-38), which is a negative regulator of inflammation capable of promoting tumor evasion of the immune system. The firm is developing an antibody cocktail derived from the B cells of COVID-19 patients who exhibited high neutralizing titers. IMM-BCP-01 targets non-overlapping regions of the Spike protein of SARS-CoV-2, which include highly conserved, subdominant epitopes. The IMM-BCP-01 program is focused on the variants of SARS-CoV-2.
665 Stockton Drive, Suite 300
Exton PENNSYLVANIA 19341
CEO: Purnanand D. Sarma
Immunome (IMNM) files prospectus for resale of 21.7 million common shares.
Immunome reports Q3 financial results with a GAAP EPS of -$0.36 and revenue of $3.57M.
Here you can normally see the latest stock twits on IMNM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.